Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2

被引:24
作者
Chan, CC
Koch, CA
Kaiser-Kupfer, MI
Parry, DM
Gutmann, DH
Zhuang, ZP
Vortmeyer, AO
机构
[1] NEI, NIH, Bethesda, MD 20892 USA
[2] NICH, NIH, Bethesda, MD USA
[3] NCI, DCEG, NIH, Bethesda, MD 20892 USA
[4] NINDS, NIH, Bethesda, MD 20892 USA
[5] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
关键词
retina; hamartoma; loss of heterozygosity; merlin; neurofibromatosis; 2; optic nerve glioma; retinal dysplasia; Lisch nodule;
D O I
10.1002/path.1174
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Individuals affected with the neurofibromatosis 2 (NF2) cancer predisposition syndrome develop specific ocular lesions. To determine whether these lesions result from altered NF2 gene expression, microdissection and PCR were used to investigate 40 ocular lesions from seven eyes of four NF2 patients for LOH, with markers that flank the NF2 gene on chromosome 22q. NF2 protein (merlin) expression was also evaluated in these lesions, using immunohistochemistry. Retinal hamartoma was observed in an seven eyes, including one with combined pigment epithelial and retinal hamartoma (CPERH). Retinal tufts were present in four eyes (three patients), retinal dysplasia in two eyes (two patients), optic nerve neurofibroma in one eye, iris naevoid hyperplasia in two eyes (two patients) and pseudophakia in all eyes. Markers were informative in three patients (six eyes from three unrelated families). One patient was non-informative due to prolonged decalcification. All retinal and optic nerve, but not iris lesions, demonstrated consistent LOH for the NF2 gene. Merlin was not expressed in the retina, optic nerve, or iris lesions. These results suggest that inactivation of the NF2 gene is associated with the formation of a variety of retinal and optic nerve lesions in NF2 patients. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 47 条
[31]  
Parry DM, 1996, AM J HUM GENET, V59, P529
[32]  
PEARSONWEBB MA, 1986, NEW ENGL J MED, V315, P1553
[33]   Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases [J].
Perry, A ;
Cai, DX ;
Scheithauer, BW ;
Swanson, PE ;
Lohse, CM ;
Newsham, IF ;
Weaver, A ;
Gutman, DH .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2000, 59 (10) :872-879
[34]   Neurofibromatosis 1 and 2 [J].
Pollack, IF ;
Mulvihill, JJ .
BRAIN PATHOLOGY, 1997, 7 (02) :823-836
[35]   The ocular presentation of neurofibromatosis 2 [J].
Ragge, NK ;
Baser, ME ;
Riccardi, VM ;
Falk, RE .
EYE, 1997, 11 (1) :12-18
[36]   CLINICAL AND GENETIC PATTERNS OF NEUROFIBROMATOSIS-1 AND NEUROFIBROMATOSIS-2 [J].
RAGGE, NK .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (10) :662-672
[37]   OCULAR ABNORMALITIES IN NEUROFIBROMATOSIS-2 [J].
RAGGE, NK ;
BASER, ME ;
KLEIN, J ;
NECHIPORUK, A ;
SAINZ, J ;
PULST, SM ;
RICCARDI, VM .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1995, 120 (05) :634-641
[38]  
Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118
[39]   Blindness, deafness, quadriparesis, and a retinal malformation: The ravages of neurofibromatosis 2 [J].
Rettele, GA ;
Brodsky, MC ;
Merin, LM ;
Teo, C ;
Glasier, CM .
SURVEY OF OPHTHALMOLOGY, 1996, 41 (02) :135-141
[40]   ALTERATION IN A NEW GENE ENCODING A PUTATIVE MEMBRANE-ORGANIZING PROTEIN CAUSES NEUROFIBROMATOSIS TYPE-2 [J].
ROULEAU, GA ;
MEREL, P ;
LUTCHMAN, M ;
SANSON, M ;
ZUCMAN, J ;
MARINEAU, C ;
HOANGXUAN, K ;
DEMCZUK, S ;
DESMAZE, C ;
PLOUGASTEL, B ;
PULST, SM ;
LENOIR, G ;
BIJLSMA, E ;
FASHOLD, R ;
DUMANSKI, J ;
DEJONG, P ;
PARRY, D ;
ELDRIGE, R ;
AURIAS, A ;
DELATTRE, O ;
THOMAS, G .
NATURE, 1993, 363 (6429) :515-521